Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in DTH (67)

Wednesday
May112016

Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.

BelsonSchmidtFernandoHardesScottBrettClark, OliveiraDavisMcHughStone.

Inflamm Res. 2016 May;65(5):389-404. doi: 10.1007/s00011-016-0923-4. Epub 2016 Mar 11.

Monday
Feb082016

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

MORENA ANTONILLI, HASSAN RAHIMI, VALERIA VISCONTI, CHIARA NAPOLETANO, ILARY RUSCITOLARIA GRAZIA ZIZZARI, SALVATORE CAPONNETTO, GIACOMO BARCHIESI, ROBERTA IADAROLA, LUCA PIERELLI, AURELIA RUGHETTI, FILIPPO BELLATI, PIERLUIGI BENEDETTI PANICI, and MARIANNA NUTI2 

 

 

Sunday
Oct282012

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N, Yamamoto A, Takesako K, Yamaguchi K, Akiyama Y

Oncol Rep. 2012 Oct;28(4):1131-8. doi: 10.3892/or.2012.1956. Epub 2012 Aug 7.

Monday
Jun252012

Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey

Bouchez C, Gervais F, Fleurance R, Palate B, Legrand JJ, Descotes J

J Toxicol Pathol. 2012 Jun;25(2):183-8.

Monday
May142012

Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial.

Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA

J Clin Oncol. 2012 May 14

 

Thursday
Dec152011

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study.

Boulton C, Meiser K, David OJ, Schmouder R

J Clin Pharmacol. 2011 Dec 15. [Epub ahead of print]

Friday
Oct282011

Response to Cutaneous Immunization with Low-Molecular-Weight Subunit Keyhole Limpet Hemocyanin

Milgrom H, Kesler K, Byron M, Harbeck R, Holliday R, Leung DY.

Int Arch Allergy Immunol. 2011 Oct 28;157(3):269-27

Wednesday
Oct052011

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.

Lesterhuis WJ, de Vries IJ, Aarntzen EA, de Boer A, Scharenborg NM, van de Rakt M, van Spronsen DJ, Preijers FW, Figdor CG, Adema GJ, Punt CJ

Br J Cancer. 2010 Oct 26;103(9):1415-21. Epub 2010 Oct 5

Tuesday
Sep062011

Higher whole-blood selenium is associated with improved immune responses in footrot-affected sheep

Jean A Hall, Rachel L Sendek, Rachel M Chinn, D Paul Bailey, Katie N Thonstad, Yongqiang Wang, Neil E Forsberg, William R Vorachek, Bernadette V Stang, Robert J Van Saun, and Gerd Bobe.

Vet Res. 2011; 42(1): 99

Thursday
Jul282011

Developmental immunotoxicity of di-n-octyltin dichloride (DOTC) in an extended one-generation reproductive toxicity study

Tonk EC, de Groot DM, Penninks AH, Waalkens-Berendsen ID, Wolterbeek AP, Piersma AH, van Loveren H.

Toxicol Lett. 2011 Jul 28;204(2-3):156-63. Epub 2011 Apr 30.

Tuesday
Jul192011

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. Epub 2011 Jul 19

Thursday
Nov112010

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. Epub 2010 Nov 11

Friday
Oct152010

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients 

Joannes F.M. Jacobs, Cornelis J.A. Punt1, W. Joost Lesterhuis, Roger P.M. Sutmuller, H. Mary-lène H. Brouwer, Nicole M. Scharenborg, Ina S. Klasen, Luuk B. Hilbrands, Carl G. Figdor, I. Jolanda M. de Vries, Gosse J. Adema

Clin Cancer Res October 15, 2010 16; 5067

Wednesday
Sep012010

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients

Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F

Br J Haematol. 2010 Sep;150(5):554-64. Epub 2010 Jul 7

Thursday
Feb182010

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

Joost P. Hegmans, Joris D. Veltman, Margaretha E. Lambers, I. Jolanda M. de Vries, Carl G. Figdor, Rudi W. Hendriks, Henk C. Hoogsteden, Bart N. Lambrecht and Joachim G. Aerts.

Am J Respir Crit Care Med. 2010 Jun 15;181(12):1383-90. Epub 2010 Feb 18

Wednesday
Sep092009

Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: role for p38 kinase

Engstrom L, Pinzon-Ortiz MC, Li Y, Chen SC, Kinsley D, Nelissen R, Fine JS, Mihara K, Manfra D.

Int Immunopharmacol. 2009 Sep;9(10):1218-27. Epub 2009 Jul 16

Friday
Aug012008

Cardiovascular Exercise Intervention Improves the Primary Antibody Response to Keyhole Limpet Hemocyanin (KLH) in Previously Sedentary Older Adults

R.W. Grant, R.A. Mariani, V. J. Vieira, M. Fleshner, T. P. Smith, K.T. Keylock, T.W. Lowder, E. McAuley, L. Hu, K. Chapman-Novakofski, and J.A. Woods.

Brain Behav Immun. 2008 August; 22(6):923-932

Tuesday
Jul012008

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.

Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ.

J Immunother. 2008 Jul-Aug;31(6):591-8.

Thursday
Oct042007

Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.

Dohnal AM, Witt V, Hügel H, Holter W, Gadner H, Felzmann T.

Cytotherapy. 2007;9(8):755-70. Epub 2007 Oct 4.

Sunday
Apr012007

Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.

Matsumoto A, Haraguchi K, Takahashi T, Azuma T, Kanda Y, Tomita K, Kurokawa M, Ogawa S, Takahashi K, Chiba S, Kitamura T.

Int J Urol. 2007 Apr;14(4):277-83.